Abstract
Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue. This chapter summarizes the key requirements for polymers used in the DES, including physical properties, stability, compatibility with drugs, biocompatibility with vascular tissue and control of drug release. An in-depth analysis of polymer structure, coating design, drug-polymer morphology and drug elution profile is provided for the four currently marketed DES: CYPHER® Sirolimus- eluting Coronary Stent, Taxus® / Taxus Liberte®, XIENCE V™ / Promus® and Endeavor®. A new generation of DES is being developed using bioabsorbable polymers which degrade over time and leave behind a bare metal stent. This includes the RES TECHNOLOGY™ platform employed in the NEVO™ Sirolimus-eluting Coronary Stent which is explored with respect to polymer composition, degradation profile and drug release kinetics.
Keywords: Polymers, Eluting Stents, drug-polymer morphology, local drug delivery, biostable, bioabsorbable, drug delivery, stent, restenosis, coronary angioplasty, neointimal hyperplasia, bare metal stent, sterilization, cobalt chromium alloy, poly(butyl methacrylate), PBMA, ethylene oxide, esters, amides, anhydrides, reendothelialization, Cypher, Xience V, Promus, Endeavor, Parylene C, Sirolimus, isobutylene, styrene, oxidation, SIBS phase, PVDF-HFP, methacrylated phosphorylcholine, lauryl methacrylate, hydroxypropyl methacrylate, trimethylsilyl methacrylate, polyorthoesters, DL-lactide, glycolide, ethylene glycol
Current Pharmaceutical Design
Title: Polymers for Drug Eluting Stents
Volume: 16 Issue: 36
Author(s): Ted Parker, Vipul Dave and Robert Falotico
Affiliation:
Keywords: Polymers, Eluting Stents, drug-polymer morphology, local drug delivery, biostable, bioabsorbable, drug delivery, stent, restenosis, coronary angioplasty, neointimal hyperplasia, bare metal stent, sterilization, cobalt chromium alloy, poly(butyl methacrylate), PBMA, ethylene oxide, esters, amides, anhydrides, reendothelialization, Cypher, Xience V, Promus, Endeavor, Parylene C, Sirolimus, isobutylene, styrene, oxidation, SIBS phase, PVDF-HFP, methacrylated phosphorylcholine, lauryl methacrylate, hydroxypropyl methacrylate, trimethylsilyl methacrylate, polyorthoesters, DL-lactide, glycolide, ethylene glycol
Abstract: Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue. This chapter summarizes the key requirements for polymers used in the DES, including physical properties, stability, compatibility with drugs, biocompatibility with vascular tissue and control of drug release. An in-depth analysis of polymer structure, coating design, drug-polymer morphology and drug elution profile is provided for the four currently marketed DES: CYPHER® Sirolimus- eluting Coronary Stent, Taxus® / Taxus Liberte®, XIENCE V™ / Promus® and Endeavor®. A new generation of DES is being developed using bioabsorbable polymers which degrade over time and leave behind a bare metal stent. This includes the RES TECHNOLOGY™ platform employed in the NEVO™ Sirolimus-eluting Coronary Stent which is explored with respect to polymer composition, degradation profile and drug release kinetics.
Export Options
About this article
Cite this article as:
Parker Ted, Dave Vipul and Falotico Robert, Polymers for Drug Eluting Stents, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454897
DOI https://dx.doi.org/10.2174/138161210794454897 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
Current Protein & Peptide Science Recent Advances in Registration Methods for MRI-TRUS Fusion Image-Guided Interventions of Prostate
Recent Patents on Engineering Inhibitors of 17β-Hydroxysteroid Dehydrogenases
Current Medicinal Chemistry Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules
Current Topics in Medicinal Chemistry An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines
Current Pharmaceutical Design Medical Evaluation of Human MicroRNAs Needs to Address Recent Sequences and GC Content
Current Regenerative Medicine (Discontinued) A Review on Fruit Juice Probiotication: Pomegranate
Current Nutrition & Food Science Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design Seq and You Will Find
Current Gene Therapy Biomarker Assessment in Nutritional Modulation of Oxidative Stress-Induced Cancer Development by Lipid-Related Bioactive Molecules
Recent Patents on Anti-Cancer Drug Discovery Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets An Overview on Applications of Gold Nanoparticle for Early Diagnosis and Targeted Drug Delivery to Prostate Cancer
Recent Patents on Nanotechnology Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy
Current Gene Therapy Bioactive Milk Lipids
Current Nutrition & Food Science Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Current Genomics